Research Papers

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

Author(s): Jian Xu, Paul J. Converse, Anna M. Upton, Khisimuzi Mdluli, Nader Fotouhi, Eric L. Nuermberger

2/2021

Tags: Bedaquiline (TMC-207), M.tb. Biology, Preclinical Data, Preclinical Models

Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis

Author(s): Dalin Rifat , Si-Yang Li , Thomas Ioerger , Keshav Shah , Jean-Philippe Lanoix , Jin Lee , Ghader Bashiri , James Sacchettini , Eric Nuermberger

12/2020

Tags: M.tb. Biology, Pretomanid/PA-824

Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units

Publication: Bioorganic & Medicinal Chemistry Letters

Author(s): Peter Choi, Hamish Sutherland, Amy S.T.Tong, Adrian Blaser, Scott Franzblau, Christopher B.Cooper, Manisha U.Lotlikar, Anna M.Upton, Jerome Guillemont, Magali Motte, Laurence Queguiner, Koen Andries, Walter Van den Broeck, William A.Denny, Brian D.Palmer

10/2017

Tags: Bedaquiline (TMC-207), Drug Discovery, M.tb. Biology

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Publication: Lancet Respiratory Medicine

Author(s): Bryant J, Harris S, Parkhill J, Dawson R, Diacon A, van Helden P, Pym A, Mahayiddin A, Chuchottaworn C, Sanne I, Louw C, Boeree M, Hoelscher M, McHugh T, Bateson A, Hunt R, Mwaigwisya S, Wright L, Gillespie S, Bentley, S.

12/2013

Tags: M.tb. Biology, ReMoxTB

Structural insight into serine protease Rv3671c that Protects M. tuberculosis from oxidative and acidic stress

Publication: Biswas T, Small J, Vandal O, et. al. Structural insight into serine protease Rv3671c that protects M. tuberculosis from oxidative and acidic stress. Structure. 2010 Oct 13;18(10):1353-63. doi: 10.1016/j.str.2010.06.017.

10/2011

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Acid Resistance in Mycobacterium tuberculosis

Publication: Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.

5/2009

Tags: Advocacy, Drug Discovery, Drug Targets, M.tb. Biology

Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment

Publication: Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1

11/2008

Tags: Drug Discovery, Drug Targets, M.tb. Biology

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery

Publication: Mdluli K, Ma Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect Disord Drug Targets. 2007 Jun;7(2):159-68. http://www.ingentaconnect.com/content/ben/iddt/2007/00000007/00000002/art00008?token=00521b85a26b1174e1f7b76504c48662a2

6/2007

Tags: Drug Discovery, Drug Targets, M.tb. Biology, MDR-TB, Preclinical Data

Antimycobacterium Agents

Publication: Ma Z, Ginsberg A, Spigelman M. Antimycobacterium Agents. Elsevier, Philadelphia, PA. 2007 Jan; 700-4, 719-20, 26.

1/2007

Tags: Clinical Development, Drug Discovery, Drug Targets, Global Pipeline, M.tb. Biology, MDR-TB, Moxifloxacin, Preclinical Models, Pretomanid/PA-824, Pyrazinamide, Rifapentine, TB-HIV, Trial Design

Novel targets for tuberculosis drug discovery

Publication: Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol. 2006 Oct;6(5):459-67. http://www.sciencedirect.com/science/article/pii/S1471489206001354. Accessed March 7, 2016

10/2006

Tags: Drug Discovery, Drug Targets, M.tb. Biology